GlassScriptPhysician profile
Amber Dawn Gillard
NPI 1174171946
$2,517.30
in general payments reported to CMS, 2019-2025
26 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $801 · 2023: $836 · 2024: $422 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.82 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.26 | 2022-2025 | Breztri, Airsupra |
| Pfizer INC. | $263.57 | 2022-2025 | |
| Lilly USA, LLC | $195.00 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $146.38 | 2023-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $106.80 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Medtronic, INC. | $97.41 | 2022-2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $94.67 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.53 | 2022 | |
| Exact Sciences Corporation | $68.55 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.98 | 2023-2025 | Jardiance |
| Madrigal Pharmaceuticals | $65.88 | 2024-2025 | Resmetirom, Rezdiffra |
| Viiv Healthcare Company | $61.38 | 2025 | Dovato |
| Novo Nordisk INC | $61.12 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $56.19 | 2023-2024 | Veozah, Myrbetriq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.76 | 2022 | |
| Bioventus LLC | $28.16 | 2022 | |
| Dexcom, INC. | $24.33 | 2023 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $24.02 | 2024 | |
| Hologic Sales and Service, LLC | $20.95 | 2022 | |
| Esperion Therapeutics, INC. | $16.77 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2022 | |
| Redhill Biopharma INC. | $14.98 | 2022 | |
| Sumitomo Pharma America, INC. | $14.91 | 2025 | Gemtesa |
| Inogen, INC. | $13.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Gillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.